Ceftin
(cefuroxime axetil)ApprovedSmall molecule
Ceftin is one of 77 small molecule programs targeting Pyelonephritis. It is currently in Approved.
3
Indications
6
Total Trials
1
Active Trials
76
Competitors
2
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
163 competitors in Urinary Tract Infection
#DrugCompanyPhaseTrials
1Maxipime
PfizerPhase 3
Medrol
PfizerPhase 3
Merrem
BB. Braun Medical Inc.
Phase 3
Ceftin
GGlaxo Dba Glaxosmithkline
Approved
Rocephin
CConrado Roberto Hoffmann Filho
Phase 3
Decadron
AAspen Global Incorporated
Phase 3
Piperacillin/tazobactam
PfizerPhase 3
Prulifloxacin
Merck & Co.Phase 3
Amoxicillin/clavulanate Potassium
Johnson & JohnsonPhase 3
Blujepa
GGlaxo Dba Glaxosmithkline
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Erythema2 trials
Urinary Tract Infection1 trial
Regulatory
FDA Approval Timeline[4]
Dec 28, 1987
CEFTIN
NDA NDA050605
Jun 30, 1994
CEFTIN
NDA NDA050672
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for cefuroxime axetil. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- GGlaxo Dba Glaxosmithkline